GreenLight Biosciences (GRNA) News Today

Canaccord Genuity Group began coverage on shares of GreenLight Biosciences in a research note on Thursday. They set a "buy" rating and a $4.00 target price on the stock.

Credit Suisse Group started coverage on shares of GreenLight Biosciences in a research report on Friday. They set an "outperform" rating and a $5.50 price target on the stock.

GreenLight Biosciences Holdings (NASDAQ:GRNA - Get Rating) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 1,770,000 shares, a decrease of 14.1% from the August 31st total of 2,060,000 shares. Based on an average trading volume of 657,700 shares, the short-interest ratio is currently 2.7 days. Currently, 3.5% of the company's shares are short sold.

GreenLight Biosciences Holdings (NASDAQ:GRNA - Get Rating) major shareholder Morningside Venture Investment purchased 3,061,224 shares of the company's stock in a transaction on Thursday, August 11th. The shares were purchased at an average price of $3.92 per share, for a total transaction of $11,999,998.08. Following the purchase, the insider now owns 15,919,155 shares in the company, valued at approximately $62,403,087.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.